Korea Research Institute of Bioscience and Biotechnology

St Pharm Co., Ltd.

Coupang, Corporation

Moon Hee Kim

Kyeong-Eun Jung

Young Ho Kim

Young Il Yeom

Hee Gu Lee

Kyung-Sook Chung

Eun Young Song

Kyung Bin Song

Misun Won

Chae Ok Yun

Yu-Kyoung Oh

Young Joo Kim

Hye Kyung Hong

Chae-Ok Yun

Seung Ho Jeong

Min Ji Yoon

Young-Joo Kim

Catherine Chang

Seon-Young Kim

Young Ju Choi

Sungwon Kim

Ho Kyung Chun

Bo Hyun Ahn

Hah Na Na

Yumi Ji

Sun-Jung Cho

Shin-Jung Choi

Kyung-Il Kim

Alexei Kayushin

Kyoung-Il Kim

Disclosed is a method of providing item information by an electronic apparatus, the method including confirming information on a first item on the basis of a first input including selection information of user acquired from a first page, confirming whether a second item having identification information corresponding to the first item is present on the basis of the information on the first item, and providing a second page having a first widget including unit price information of the first item and unit price information of the second item and a second widget including payment amount information, in response to a second input for item purchase, when the second item is present and the unit price information of the second item is lower than the unit price information of the first item.

Operating method, electronic apparatus, and user device for offering item information and electronic apparatus supporting thereof

The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.

Pharmaceutical composition for treating cancer

The present invention provides a method for preparing nucleotide oligomers, including (a) coupling a nucleotide dimer or nucleotide trimer to a nucleoside attached to solid supports or to universal solid supports as a starting material; (b) sequentially coupling nucleotide monomers to the resulting structures of Step (a) to prepare a nucleotide oligomer; and (c) removing the nucleotide oligomers from the solid supports. The method of the present invention provides nucleotide oligomers having 15-20% higher purity than the conventional art. The present invention enables the efficient and inexpensive synthesis of nucleotide oligomers with high purity within a shorter period of time.

Preparation of nucleotide oligomer

Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.

Use of FLJ25416 gene

Growing community of inventors

Seoul, South Korea

Moon Hee Kim